id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-310974-hz37yf39	Crolley, Valerie E.	COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study	2020-10-23		.txt	text/plain	3538	176	48	The primary outcome of this study was to evaluate the association between a diagnosis of COVID-19 and mortality in oncology patients on active systemic anti-cancer treatment. This is reflected in work elsewhere, including a European study of 890 patients which reported worse outcomes in haematological cancer patients infected with COVID-19, 9,20 as well as data from Hubei, China. Alternatively, other studies found that treatment with immunotherapy did not impact mortality negatively in COVID-19 positive cancer patients, 11 and it is hypothesised that immunotherapy may reduce the risk of developing the cytokine storm primarily responsible for the development of ARDS in COVID-19. Patients on active cancer treatment are more likely to be infected with COVID-19 if they are being treated with chemotherapy, particularly high-dose chemotherapy; treatment with immunotherapy and hormonal treatments had no significant impact on the chances of contracting COVID-19, while targeted treatment appeared to have a protective effect.	./cache/cord-310974-hz37yf39.txt	./txt/cord-310974-hz37yf39.txt